← Oncology Approval Tracker

FDA DECISION ·

Unloxcyt

cosibelimab-ipdl · Checkpoint Therapeutics

FDA approvalNew therapyCutaneous squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic or locally advanced cutaneous squamous cell carcinoma for whom curative surgery or radiation is not an option.

LAMPGEN ANALYSIS

Why it matters

This PD-L1 antibody adds an option for advanced cutaneous squamous cell carcinoma when curative local treatment is unsuitable.

What research teams should watch

Document the multidisciplinary rationale for foregoing surgery or radiation and standardize assessment of external lesions.

PRIMARY RECORDS

Sources